Cover Image
市場調查報告書

EpiCast Report:肝細胞癌症 (HCC) - 至2024年的流行病學預測

EpiCast Report: Hepatocellular Carcinoma - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 345647
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:肝細胞癌症 (HCC) - 至2024年的流行病學預測 EpiCast Report: Hepatocellular Carcinoma - Epidemiology Forecast to 2024
出版日期: 2015年11月01日 內容資訊: 英文 57 Pages
簡介

在 全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本),肝細胞癌症 (HCC) 和確診的患者數,從2014年的103,308人預計今後10年達到123,658人,1.97%的年度成長率。

本報告提供全球主要7個國家的肝細胞癌症 (HCC) 調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 肝細胞癌症 (HCC) 的流行病學預測
    • HCC和確診的患者數
    • HCC和確診的患者數 (各年齡)
    • HCC和確診的患者數 (性別)
    • HCC和確診的患者數 (年齡標準化) 、等
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER102-15

Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver. HCC is classified by various staging systems such as the Barcelona Clinic Liver Cancer (BCLC) stage and Child Pugh stages. The major risk factors for HCC are hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and alcohol abuse. HCC is more common in men than women, averaging between two to four times as many cases in men as in women. This could be due to men being more likely to be infected with HBV and HCV, to consume more alcohol, to smoke cigarettes, or to have increased iron stores.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HCC will increase from 103,308 cases in 2014 to 123,658 cases in 2024 at an Annual Growth Rate (AGR) of 1.97%. Japan had the highest number of diagnosed incident cases of HCC among the 7MM throughout the forecast period. In the 7MM in 2014 there were 38,359 diagnosed incident cases of BCLC stage A, 26,558 cases of BCLC stage B, 26,527 cases of BCLC stage C, and 11,865 cases of BCLC stage D. GlobalData epidemiologists estimated that the 7MM in 2014 had 150,488 five-year diagnosed prevalent cases of HCC, 10,835 diagnosed incident cases of HCC with HBV, and 62,140 diagnosed incident cases of HCC with HCV.

The overall increase in the incidence of HCC in the 7MM was mostly driven by population changes, as GlobalData epidemiologists observed very little historical changes in the incidence of HCC. During the forecast period, changes in alcohol use/abuse among men and women may impact the incidence of HCC in the US and UK. Furthermore, the high prevalence of HCV in Italy and Japan will continue to contribute to HCC incidence.

GlobalData's epidemiological forecast for the diagnosed incident and the five-year diagnosed prevalent cases of HCC in the 7MM is supported by age- and sex-specific data for the incidence. The one- to five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific, population-based studies that are representative of the national population in the respective markets.

Scope

  • The Hepatocellular Carcinoma (HCC) EpiCast Report provides an overview of the risk factors and global trends of HCC in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of HCC in these markets. The diagnosed incident cases of HCC are segmented by age (30-39 years, 40-49 years, 50-59 years, 60-69 years, and 70-79 years, =80 years), sex, BCLC stage at diagnosis, and comorbidity with HBV or HCV.
  • The HCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The HCC EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HCC market.
  • Quantify patient populations in the global HCC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HCC therapeutics in each of the markets covered.
  • Identify the percentage of HCC incident cases by stage at diagnosis and comorbidity with HBV or HCV.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Relative Survival
    • 3.3.3. Stage at Diagnosis
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of HCC (2014-2024)
    • 3.5.1. Diagnosed Incident Cases of HCC
    • 3.5.2. Age-Specific Diagnosed Incident Cases of HCC
    • 3.5.3. Sex-Specific Diagnosed Incident of HCC
    • 3.5.4. Age-Standardized Diagnosed Incidence of HCC
    • 3.5.5. Diagnosed Incident Cases of HCC by BCLC Stages
    • 3.5.6. Diagnosed Incident Cases of HCC with HBV and HCV Comorbidities
    • 3.5.7. Five-Year Diagnosed Prevalent Cases of HCC
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. Physicians and Specialists Included in this Study
  • 4.3. Primary Research - Prescriber Survey
  • 4.4. About the Authors
    • 4.4.1. Epidemiologists
    • 4.4.2. Reviewers
    • 4.4.3. Global Director of Therapy Analysis and Epidemiology
    • 4.4.4. Global Head of Healthcare
  • 4.5. About GlobalData
  • 4.6. About EpiCast
  • 4.7. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for HCC
  • Table 2: 7MM, Most Recent One-Year and Five-Year Relative Liver Cancer Survival in Men and Women
  • Table 3: US and Germany, Relative Survival Temporal Trend
  • Table 4: 7MM, BCLC and Child Pugh Stage at Diagnosis, Men and Women (%)
  • Table 5: 7MM, Sources Used for Diagnosed Incidence of HCC
  • Table 6: 7MM, Sources of Epidemiological Data Used for Diagnosed Incident Cases Segmented by BCLC Clinical Stages
  • Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Five-Year Diagnosed Prevalent Cases of HCC
  • Table 8: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Incident Cases of HCC with HBV and HCV comorbidities.
  • Table 9: 7MM, Diagnosed Incident Cases of HCC, Both Sexes, Ages ≥30 years, N, 2014-2024
  • Table 10: 7MM, Age-Specific Diagnosed Incident Cases of HCC, Both Sexes, N, 2014
  • Table 11: 7MM, Sex-Specific Diagnosed Incident Cases of HCC, Ages ≥30 Years, N (Row %), 2014
  • Table 12: 7MM, Diagnosed Incident Cases of HCC by BCLC Stage, Ages ≥30 Years, N (Row %), 2014
  • Table 13: 7MM, Diagnosed Incident Cases of HCC with HBV and HCV, Ages ≥30 years, Both Sexes, N, 2014 (Row %)
  • Table 14: 7MM, Five-Year Diagnosed Prevalent Cases of HCC, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Table 15: High-Prescribing Physicians (non-KOL) Surveyed, By Country

List of Figures

  • Figure 1: 7MM, Diagnosed Incidence Rate of HCC (Cases per 100,000 Population), Ages ≥30 Years, Both Sexes, 2004-2013
  • Figure 2: 7MM, Diagnosed Incident Cases of HCC, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 3: 7MM, Age-Specific Diagnosed Incident Cases of HCC, Both Sexes, N, 2014
  • Figure 4: 7MM, Diagnosed Incident Cases of HCC, Ages ≥30 Years, N, 2014
  • Figure 5: 7MM, Age-Standardized Diagnosed Incidence Cases of HCC, Ages ≥30 Years, N, 2014
  • Figure 6: 7MM, Diagnosed Incident Cases of HCC by BCLC Stage, Ages ≥30 Years, Both Sexes N, 2014
  • Figure 7: 7MM, Diagnosed Incident Cases of HCC with HCV, Ages ≥30 Years, N, 2014
  • Figure 8: 7MM, Five-Year Diagnosed Prevalent Cases of HCC, Ages ≥30 Years, Both Sexes, N, 2014-2024
Back to Top